`
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`EDWARDS LIFESCIENCES CORPORATION,
`
`
`
`Petitioner,
`
`v.
`
`ENDOHEART AG,
`
`Patent Owner.
`
`____________
`
`Case IPR2016-00300
`
`U.S. Patent No. 8,182,530
`
`____________
`
`PETITIONER’S MOTION UNDER 37 C.F.R. § 42.104(c)
`TO CORRECT PETITION
`
`
`
`
`Petitioner’s Motion Under 37 C.F.R. § 42.104(c)
`Case IPR2016-00300
`U.S. Patent No. 8,182,530
`
`
`Petitioner, Edwards Lifesciences Corporation (“Edwards”), requests
`
`permission under 37 C.F.R. § 42.104(c) to file a corrected Petition to fix a clerical
`
`error in the Real Party-in-Interest section of the Mandatory Notices in its Petition.
`
`Pursuant to Rule 42.8(b)(1), Petitioner correctly identified Edwards Lifesciences
`
`Corporation and Edwards Lifesciences, LLC as the two real parties-in-interest.
`
`Petitioner, however, mis-transcribed the relationship between the two parties in the
`
`Mandatory Notices section of the Petition, information not required, per se,
`
`pursuant to the rules. Petitioner’s authorization to file this Motion was given by
`
`the Board and documented in the Order of March 8, 2016. See Paper 6.
`
`I.
`
`Background
`
`Edwards filed a Petition seeking inter partes review (“IPR”) of U.S. Patent
`
`No. 8,182,530 (the ‘530 patent) on December 9, 2015. In preparing its Petition,
`
`however, Edwards’ counsel made a clerical error by inadvertently mis-transcribing
`
`that Edwards Lifesciences, LLC is the parent company of Edwards Lifesciences
`
`Corporation. See IPR2016-00300, Paper 2 at 20.
`
`Edwards first noticed this error on February 17, 2016 when Endoheart AG’s
`
`(“Endoheart’s”) counsel, Mr. Edward Arons, sent an email correspondence to
`
`Edwards’ counsel of record, identifying a discrepancy found in the Mandatory
`
`Notices section of the Petition regarding the relationship between the two Edwards
`
`
`
`
`
`2
`
`
`
`Petitioner’s Motion Under 37 C.F.R. § 42.104(c)
`Case IPR2016-00300
`U.S. Patent No. 8,182,530
`
`
`Lifesciences entities. Endoheart reserved the right to oppose Edwards filing a
`
`revised Petition correcting the clerical or typographical error.
`
`Edwards includes with the revised Petition a Declaration of Ruby J.
`
`Natnithithadha (attached as Ex. 1046), attesting to the facts surrounding the clerical
`
`error, and a printout from SEC’s website (attached as Ex. 1047) plainly showing
`
`that Edwards Lifesciences Corporation is the parent company of Edwards
`
`Lifesciences, LLC.
`
`I. Edwards’ Correction Will Not Substantively Effect the Requested
`
`Relief
`
`When determining whether to grant a motion to correct a Petition under
`
`37 C.F.R. § 42.104(c), the Board considers “any substantial substantive effect,
`
`including any effect on the patent owner’s ability to file a preliminary response.”
`
`77 Fed. Reg. 48680, 48699. Further, the Board has previously noted that “this rule
`
`is remedial in nature and therefore is entitled to a liberal interpretation.” See ABB
`
`Inc. v. ROY-G-BIV Corp., IPR2013-00063, Paper 21 at 7 (Jan. 16, 2013) (citing
`
`Tcherepnin v. Knight, 389 U.S. 332, 336 (1967)). For the reasons provided next,
`
`Edwards respectfully submits that the requested change to its Petition, correcting
`
`the relationship between the two Edwards’ entities identified in the Mandatory
`
`
`
`
`
`3
`
`
`
`Petitioner’s Motion Under 37 C.F.R. § 42.104(c)
`Case IPR2016-00300
`U.S. Patent No. 8,182,530
`
`Notices section of the Petition, will not have any “substantial substantive effect” on
`
`this proceeding.
`
`37 CFR 42.8(a)(1) requires a Petitioner to file Mandatory Notices as part of
`
`its Petition, and Rule 42.8(b)(1) requires a notice identifying “each real party-in-
`
`interest for the party.” Importantly, Rule 42.8(b)(1) does not require a notice
`
`identifying the relationship between any two or more real parties-in-interest. As
`
`the requested correction regards information not required by Rule 42.8, it will have
`
`no impact on this proceeding. In particular, allowing Edwards to correctly identify
`
`that Edwards Lifesciences, LLC as a wholly owned entity of Edwards Lifesciences
`
`Corporation will not prejudice Endoheart or add any substantive information to this
`
`IPR required by law or regulation. The Petition, as-filed, including the clerical
`
`error sought to be corrected here, did not affect Endoheart’s ability to file the
`
`Preliminary Response dated March 15, 2016. See Paper 7. Edwards submits that
`
`the requested relief would benefit the public by providing a more accurate public
`
`record.
`
`Accordingly, Petitioner requests permission under 37 C.F.R. § 42.104(c) to
`
`file a Replacement Petition (attached hereto as Ex. 1045) for entry into the public
`
`record.
`
`
`
`
`
`
`
`4
`
`
`
`Petitioner’s Motion Under 37 C.F.R. § 42.104(c)
`Case IPR2016-00300
`U.S. Patent No. 8,182,530
`
`
`The Patent Trial and Appeal Board is hereby authorized to charge any fees
`
`associated with this proceeding to Deposit Account 15-0030 (Customer ID No.
`
`Respectfully submitted,
`Oblon, McClelland, Maier &
`Neustadt, LLP
`
`
`
`
`
`/W. Todd Baker /
`W. Todd Baker
`Reg. No. 45,265
`Attorney for Petitioner
`Edwards Lifesciences Corporation
`
`
`
`22850).
`
`
`
`
`
`
`
`
`
`
`Dated: March 22, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Customer Number
` 22850
`Tel. (703) 413-3000
`Fax. (703) 413-2220
`
`
`
`
`
`5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. § 42.6(e), the undersigned certifies service of
`
`PETITIONER’S MOTION UNDER 37 C.F.R. 42.104(c) along with Exhibits
`
`1045-1047 on the counsel of record for the Patent Owner by filing this document
`
`through the Patent Review Processing System as well as delivering a copy via
`
`electronic mail to the following addresses:
`
`Edward M. Arons
`earons@weissarons.com
`
`Joel Weiss
`jweiss@weissarons.com
`Endoheart-IPR@weissarons.com
`
`Dated: March 22, 2016
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` /W. Todd Baker /
`
`W. Todd Baker
`Reg. No. 45,265